Entera Bio Ltd. ENTX 深 滬
等待開盤 09-03 09:30:00 美东时间
1.98
+0.050
+2.59%
華盛通- 最 高2.01
- 今 開1.93
- 成交量 6.64万股
- 最 低 1.93
- 昨 收 1.93
- 總市值 8999.54万
- 52周最高 2.79
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.5006
- 委 比 98.02%
- 總股本 4545.22万
- 歷史最高 10.16
- 量 比 2.09
- 振 幅 4.15%
- 歷史最低 0.472
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
Entera Bio Ltd. will present data on three key programs in September 2025. At the ASBMR Annual Meeting, they will discuss EB613, an oral PTH(1-34) tablet for postmenopausal osteoporosis, and next-gen EB613. At ESPEN, they will present on an oral GLP-2 analog for short bowel syndrome. CEO Miranda Toledano will also provide a corporate overview at the H.C. Wainwright Investor Conference.
08-28 12:00
Entera Bio Q2 EPS $(0.06) Misses $1.21 Estimate
Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $1.21 by 104.96 percent. This is unchanged from the same period last year.
08-09 04:10
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
Entrada Therapeutics reported Q2 2025 financial results and highlighted key milestones, including the first patient dosed in the ELEVATE-44-201 study and initiation of ELEVATE-45-201. Multiple clinical trial sites in the U.K. and EU are activated. The company expanded its leadership team with Navid Khan, PhD, and Kiran Patki, MD, to support its growing pipeline. Cash reserves of $354 million are expected to fund operations into Q2 2027. Data from...
08-06 11:00
Entera Bio Advances EB613 with FDA Approval
The latest update is out from Entera Bio ( ($ENTX) ). On July 28, 2025, Entera ...
07-28 19:59
Entera Bio Receives FDA Agreement To Support EB613 NDA Filing With Single 24-Month Global Phase 3 Study In Postmenopausal Osteoporosis, Using Total Hip BMD As Primary Endpoint And Vertebral Fracture Incidence As Key Secondary
Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S. Food and Drug Administration
07-28 19:32
Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis
Entera Bio announced that the FDA has agreed to support the NDA filing for EB613, an oral osteoanabolic treatment for postmenopausal osteoporosis, with a single Phase 3 study. The study will use change in total hip BMD as the primary endpoint, marking a shift from traditional fracture-based primary endpoints. The company highlights EB613 as the first oral, daily anabolic tablet aiming to address the unmet need for an alternative to injectable tre...
07-28 11:30
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
OPKO Health 和 Entera Bio 宣布，他们关于短肠综合征治疗的新型口服 GLP-2 类似物的研究摘要，被选中在 2025 年欧洲临床营养与代谢学会年会上展示。该疗法结合了 OPKO 的长效 GLP-2 激动剂和 Entera 的 N-Tab™ 技术，为短肠综合征患者提供更便捷的口服选择，目前唯一获批的 GLP-2 激动剂需每日注射。摘要强调了口服形式的潜在优势，如提高患者依从性及个性化治疗的可能。短肠综合征是一种罕见、可能危及生命的吸收障碍性疾病，影响约 3 万名美国和欧盟患者，市场规模庞大。OPKO 和 Entera 的合作旨在通过创新技术改善这类患者的治疗方案。
07-08 12:00
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
Entera Bio Ltd. announced that new data on the dual actions of EB613, a once-daily oral PTH(1-34) tablet for postmenopausal women with osteoporosis, has been selected for an oral presentation at the ASBMR 2025 Annual Meeting in Seattle. The Phase 2 study showed EB613 significantly increased bone mineral density (BMD) and demonstrated dual effects on bone formation and resorption. EB613 aims to address the treatment gap for high-risk osteoporosis ...
06-26 12:00
OPKO Health And Entera Bio Say New Pharmacologic And Pharmacokinetic In Vivo Data For Investigational Oral OPK-88006 Tablet Treatment Selected For Presentation At ENDO 2025 Annual Meeting
OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected
06-25 20:12
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
OPKO Health和Entera Bio宣布，其研究性口服药物OPK-88006在ENLO 2025会议上展示新数据。该药结合GLP-1和胰高血糖素，设计为每日口服或每周注射，用于肥胖及相关代谢病。双方计划今年向FDA提交IND申请，并开展1期临床试验。
06-25 12:00
